Patents by Inventor Joseph V. Briggman

Joseph V. Briggman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection and treatment of prostate cancer
    Publication number: 20020164664
    Abstract: The invention provides a wide range of methods and compositions for detecting and treating prostate cancer in an individual. Specifically, the invention provides target prostate cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of prostate cancer. The target prostate cancer-associated protein may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of prostate cancer in an individual. In addition, the invention provides methods utilizing the prostate cancer-associated proteins either as targets for treating prostate cancer or as indicators for monitoring the efficacy of such a treatment.
    Type: Application
    Filed: November 30, 2001
    Publication date: November 7, 2002
    Applicant: Matritech, Inc.
    Inventors: John J. Hlavaty, Joseph V. Briggman
  • CEA-binding protein and uses thereof
    Patent number: 5281697
    Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 20 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO:4. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: January 25, 1994
    Assignees: Applied Biotechnology, Inc., New England Deacons Hospital Corp.
    Inventors: Carol A. Toth, Peter Thomas, Sibusisiwe M. Maswoswe, Joseph V. Briggman
  • Binding protein for CEA and uses thereof
    Patent number: 5278290
    Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 21 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO: 2. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: January 11, 1994
    Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital, Corp.
    Inventors: Peter Thomas, Carol A. Toth, Sibusisiwe M. Maswoswe, Joseph V. Briggman
  • Method for isolating CEA-binding protein
    Patent number: 5245017
    Abstract: Disclosed are methods of isolating a protein which binds carcinoembryonic antigen. These methods include the following steps. A biological sample containing carcinoembryonic antigen (CEA) and a CEA-binding protein (CBP) is provided and contacted with a divalent cation at a concentration and for a time sufficient to allow the binding of the CBP to CEA, thereby forming a CBP-CEA conjugate. The sample is then contacted with an adsorbent that binds CEA for a time sufficient to allow adsorbance to the adsorbent. Portions of the sample not adsorbed are removed. The CBP is then disassociated from the conjugate and is collected.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: September 14, 1993
    Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital Corporation
    Inventors: Sibusisiwe M. Maswoswe, Joseph V. Briggman, Carol A. Toth, Peter Thomas